ZA201208510B - Nitrogen heterocyclic compounds useful as pde10 inhibitors - Google Patents

Nitrogen heterocyclic compounds useful as pde10 inhibitors

Info

Publication number
ZA201208510B
ZA201208510B ZA2012/08510A ZA201208510A ZA201208510B ZA 201208510 B ZA201208510 B ZA 201208510B ZA 2012/08510 A ZA2012/08510 A ZA 2012/08510A ZA 201208510 A ZA201208510 A ZA 201208510A ZA 201208510 B ZA201208510 B ZA 201208510B
Authority
ZA
South Africa
Prior art keywords
heterocyclic compounds
compounds useful
nitrogen heterocyclic
pde10 inhibitors
pde10
Prior art date
Application number
ZA2012/08510A
Other languages
English (en)
Inventor
Robert M Rzasa
Akexander J Pickrell
Essau Hu Harrington
Jian J Chen
Wenge Zhong
Shannon Rumfelt
Qingyian Liu
Michael J Frohn
Jennifer R Allen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44278966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201208510(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA201208510B publication Critical patent/ZA201208510B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2012/08510A 2010-05-13 2012-11-12 Nitrogen heterocyclic compounds useful as pde10 inhibitors ZA201208510B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33452510P 2010-05-13 2010-05-13
PCT/US2011/036148 WO2011143365A1 (en) 2010-05-13 2011-05-11 Nitrogen heterocyclic compounds useful as pde10 inhibitors

Publications (1)

Publication Number Publication Date
ZA201208510B true ZA201208510B (en) 2017-11-29

Family

ID=44278966

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/08510A ZA201208510B (en) 2010-05-13 2012-11-12 Nitrogen heterocyclic compounds useful as pde10 inhibitors

Country Status (26)

Country Link
US (3) US8957073B2 (enExample)
EP (1) EP2569300A1 (enExample)
JP (1) JP5702855B2 (enExample)
KR (1) KR101564806B1 (enExample)
CN (1) CN103221404B (enExample)
AR (1) AR081627A1 (enExample)
AU (1) AU2011253057B2 (enExample)
BR (1) BR112012029026A2 (enExample)
CA (1) CA2798490A1 (enExample)
CL (1) CL2012003178A1 (enExample)
CO (1) CO6630189A2 (enExample)
CR (1) CR20120635A (enExample)
EA (1) EA201291236A1 (enExample)
IL (1) IL222898A (enExample)
MA (1) MA34300B1 (enExample)
MX (1) MX2012013130A (enExample)
NZ (1) NZ603876A (enExample)
PE (1) PE20130576A1 (enExample)
PH (1) PH12012502212A1 (enExample)
SG (1) SG185515A1 (enExample)
TN (1) TN2012000530A1 (enExample)
TW (1) TW201206902A (enExample)
UA (1) UA109438C2 (enExample)
UY (1) UY33382A (enExample)
WO (1) WO2011143365A1 (enExample)
ZA (1) ZA201208510B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2798325A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
WO2011143365A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
RU2013142364A (ru) 2011-02-18 2015-03-27 Аллерган, Инк. Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а)
HUE059230T2 (hu) * 2011-06-10 2022-10-28 Merck Patent Gmbh Vegyületek és eljárások BTK-inhibitor aktivitású pirimidin és piridin vegyületek elõállítására
US8623860B2 (en) * 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
TW201348231A (zh) * 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
CN104271568B (zh) * 2012-05-09 2016-05-04 硕腾服务有限责任公司 作为抗寄生虫剂的氮杂环丁烷衍生物
UY34858A (es) 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP3763367A1 (en) 2012-12-06 2021-01-13 Celgene Quanticel Research, Inc. Pyridine-pyrazole derivatives as histone demethylase inhibitors
EP2953939A1 (en) * 2013-02-07 2015-12-16 Merck Patent GmbH Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
LT3105226T (lt) 2014-02-13 2019-11-11 Incyte Corp Ciklopropilaminai, kaip lsd1 inhibitoriai
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
KR20160122215A (ko) * 2014-02-14 2016-10-21 다케다 야쿠힌 고교 가부시키가이샤 Gpr6의 피라진 조절제
CN104016909B (zh) * 2014-04-03 2016-04-20 定陶县友帮化工有限公司 一种2-氨基-3-溴-5-氯吡啶的合成方法
CN104016911A (zh) * 2014-04-03 2014-09-03 定陶县友帮化工有限公司 一种2-氨基-3,5-二溴吡啶的合成方法
CN106536518B (zh) * 2014-05-19 2020-05-12 勃林格殷格翰动物保健美国公司 驱蠕虫化合物
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
JP6769963B2 (ja) 2014-08-29 2020-10-14 ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
WO2016054560A1 (en) * 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
WO2017184934A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
WO2017205425A1 (en) * 2016-05-24 2017-11-30 President And Fellows Of Harvard College Compounds for organic light emitting diode materials
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
GEAP202115110A (en) 2016-12-16 2021-02-25 Pfizer Inc Glp-1 receptor agonists and uses thereof
HUE057710T2 (hu) 2017-01-23 2022-05-28 Cadent Therapeutics Inc Káliumcsatorna modulátorok
CN106957300A (zh) * 2017-04-12 2017-07-18 苏州汉德创宏生化科技有限公司 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基）吡啶二盐酸盐的合成方法
WO2019084338A1 (en) * 2017-10-25 2019-05-02 University Of South Florida DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
LT3786160T (lt) 2017-10-27 2022-09-26 Boehringer Ingelheim International Gmbh Piridino dariniai ir jų terapinis panaudojimas kaip trpc6 inhibitorių
US20210024498A1 (en) * 2017-12-26 2021-01-28 Mediconns (Shanghai) Biopharmaceutical Co., Ltd Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
CA3103051C (en) 2018-06-15 2023-01-17 Pfizer Inc. Glp-1 receptor agonists and uses thereof
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
JP7485660B2 (ja) 2018-10-02 2024-05-16 シンジェンタ パーティシペーションズ アーゲー 殺有害生物性活性ベンゼン－及びアジン－アミド化合物
JP2022508945A (ja) 2018-10-22 2022-01-19 カデント セラピューティクス，インコーポレーテッド カリウムチャネルモジュレーターの結晶形態
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
MX2021006034A (es) * 2018-11-22 2021-09-21 Qilu Regor Therapeutics Inc Agonistas de glp-ir y usos de los mismos.
WO2020110964A1 (ja) 2018-11-26 2020-06-04 京セラ株式会社 ガスノズルおよびガスノズルの製造方法ならびにプラズマ処理装置
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TWI853009B (zh) 2019-03-29 2024-08-21 瑞士商先正達農作物保護公司 殺有害生物活性之二-醯胺化合物
MA55500A (fr) 2019-04-05 2022-02-09 Syngenta Crop Protection Ag Composés de diazine-amide à action pesticide
MA55587A (fr) 2019-04-11 2022-02-16 Syngenta Crop Protection Ag Composés diazine-amide à action pesticide
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
MX2021012492A (es) 2019-04-12 2021-11-12 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos.
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
US20220289715A1 (en) 2019-08-23 2022-09-15 Syngenta Crop Protection Ag Pesticidally active pyrazine-amide compounds
JP7534390B2 (ja) * 2019-09-12 2024-08-14 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
US11702404B2 (en) 2019-10-25 2023-07-18 Gilead Sciences, Inc. GLP-1R modulating compounds
MA57692B1 (fr) * 2019-11-15 2025-04-30 Ildong Pharmaceutical Co., Ltd. Agoniste du récepteur glp-1 et son utilisation
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
PL4097097T3 (pl) 2020-01-29 2025-05-12 Gilead Sciences, Inc. Związki modulujące glp-1r
KR102563111B1 (ko) * 2020-03-18 2023-08-04 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
PE20230175A1 (es) * 2020-03-18 2023-02-01 Lg Chemical Ltd Agonista del receptor de glp-1, composicion farmaceutica que comprende el mismo, y metodo para preparar el mismo
JP2023537963A (ja) 2020-08-13 2023-09-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 統合失調症に伴う認知機能障害に対する処置法
JP2023545808A (ja) 2020-10-13 2023-10-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 再加工方法
KR20230109709A (ko) * 2020-11-19 2023-07-20 세레신 인코포레이티드 알츠하이머병, 인지 장애 및 기타 뇌 변화 질환의 방사성 의약품 케톤 및 이중 추적자 영상
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
US12264149B2 (en) 2020-12-30 2025-04-01 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
CA3220005A1 (en) 2021-05-13 2022-11-17 Carmot Therapeutics Inc. Modulators of g-protein coupled receptors
US20240287047A1 (en) 2021-06-09 2024-08-29 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
IL308122A (en) * 2021-06-16 2023-12-01 Celgene Corp Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases
US12018015B2 (en) 2021-06-18 2024-06-25 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
MX2024003872A (es) 2021-09-27 2024-04-19 Terns Pharmaceuticals Inc Acidos carboxilicos de benzimidazol como agonistas de glp-1r.
EP4422745A1 (en) 2021-10-25 2024-09-04 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
AU2022415440A1 (en) 2021-12-16 2024-05-30 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
MX2024010346A (es) 2022-02-23 2024-08-30 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r.
TWI866545B (zh) * 2022-10-20 2024-12-11 南韓商東亞Ｓｔ股份有限公司 氮雜環丁烷基苯并唑化合物及其等作為mer及axl抑制劑的用途
TW202506131A (zh) 2023-04-07 2025-02-16 美商拓臻製藥公司 ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法
WO2025147609A1 (en) * 2024-01-05 2025-07-10 Dewpoint Therapeutics, Inc. Amino quinoline compounds and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GT200200188A (es) 2001-09-24 2003-06-25 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
DK2527315T3 (da) * 2002-05-31 2014-06-02 Proteotech Inc Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
US7582761B2 (en) * 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
GB0325287D0 (en) * 2003-10-29 2003-12-03 Merck Sharp & Dohme Therapeutic agents
CN1984901B (zh) * 2004-05-18 2011-02-09 先灵公司 用作pde4抑制剂的取代的2-喹啉基-*唑
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20070072908A1 (en) * 2005-06-08 2007-03-29 Japan Tobacco Inc. Heterocyclic compounds
WO2007076104A1 (en) * 2005-12-23 2007-07-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20100222353A1 (en) * 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
US8003649B2 (en) * 2007-12-21 2011-08-23 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
US20110294836A1 (en) 2008-06-20 2011-12-01 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
KR101753826B1 (ko) * 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,２,４―트리아졸로［４,３―ａ］피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
JP5696856B2 (ja) 2009-09-03 2015-04-08 バイオエナジェニックス Ｐａｓｋの阻害用複素環式化合物
US8802679B2 (en) 2009-09-16 2014-08-12 Astellas Pharma Inc. Glycine compound
WO2011143365A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
CA2798325A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
UY34858A (es) 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Also Published As

Publication number Publication date
WO2011143365A1 (en) 2011-11-17
JP2013526536A (ja) 2013-06-24
CN103221404B (zh) 2015-12-16
CR20120635A (es) 2013-01-30
US20160102075A1 (en) 2016-04-14
IL222898A0 (en) 2012-12-31
PE20130576A1 (es) 2013-05-19
KR101564806B1 (ko) 2015-10-30
US20110306587A1 (en) 2011-12-15
AU2011253057B2 (en) 2014-11-20
TN2012000530A1 (en) 2014-04-01
TW201206902A (en) 2012-02-16
US20140213572A1 (en) 2014-07-31
UA109438C2 (uk) 2015-08-25
MA34300B1 (fr) 2013-06-01
JP5702855B2 (ja) 2015-04-15
EP2569300A1 (en) 2013-03-20
EA201291236A1 (ru) 2013-11-29
AR081627A1 (es) 2012-10-10
CA2798490A1 (en) 2011-11-17
CL2012003178A1 (es) 2013-07-05
CN103221404A (zh) 2013-07-24
CO6630189A2 (es) 2013-03-01
AU2011253057A1 (en) 2012-11-29
PH12012502212A1 (en) 2013-02-04
US8957073B2 (en) 2015-02-17
IL222898A (en) 2015-11-30
UY33382A (es) 2011-10-31
MX2012013130A (es) 2013-04-11
US9718803B2 (en) 2017-08-01
NZ603876A (en) 2015-02-27
BR112012029026A2 (pt) 2016-08-02
KR20130065666A (ko) 2013-06-19
SG185515A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
ZA201208510B (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
HRP20180552T1 (hr) Derivati piperidin-4-il azetidina kao inhibitori jak1
IL257104B (en) Macrocyclic compounds as trk kinase inhibitors
IL246882A0 (en) Amino-heterocyclic compounds used as pde9 inhibitors
ZA201301951B (en) Benzimidazole derivatives as p13 kinase inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
ZA201209119B (en) Nitrogen containing heteroaryl compounds
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
ZA201206450B (en) Heterocyclic amides as rock inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
IL223131A0 (en) Heterocyclic compounds as janus kinase inhibitors
EP2379538A4 (en) HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
EP2611806A4 (en) HETEROCYCLIC COMPOUNDS ENRICHED IN DEUTERIUM AS INHIBITORS OF KINASES
HK1187333A (en) Heterocyclic compounds as dgat1 inhibitors